What is the next big thing for your company's portfolio?

To help pharmaceutical companies answer this question, Kaiser Associates conducted a comprehensive analysis of nearly every pharma R&D program in the world and compiled the findings into the second annual Hot Indications List.

The 2016 edition includes:
  • An updated Top 200 List of indications
  • Analysis of some of the biggest 'movers and losers' from last year's list
  • Insights on recent acquisitions, drug approvals, and pipeline activity

Complete the form to download your free whitepaper now!

 

Have you seen our Oncology and Immunology Deep Dives? Click to download.